drugset / Trial / NCT07521007
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.
Timeline
- Start
- 2026-07-31
- Primary completion
- 2027-07-31
- Completion
- 2029-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YN001 | Unknown | 20 mg | Intravenous |
| Subject | YN001 | Unknown | 40 mg | Intravenous |